TR200401007T4 - Azabisiklik karbamatlar ve bunların, alfa-7 nikotinik asetilkolin reseptör agonistleri olarak kullanımları - Google Patents

Azabisiklik karbamatlar ve bunların, alfa-7 nikotinik asetilkolin reseptör agonistleri olarak kullanımları

Info

Publication number
TR200401007T4
TR200401007T4 TR2004/01007T TR200401007T TR200401007T4 TR 200401007 T4 TR200401007 T4 TR 200401007T4 TR 2004/01007 T TR2004/01007 T TR 2004/01007T TR 200401007 T TR200401007 T TR 200401007T TR 200401007 T4 TR200401007 T4 TR 200401007T4
Authority
TR
Turkey
Prior art keywords
alpha
formula
carbamates
receptor agonists
acetylcholine receptor
Prior art date
Application number
TR2004/01007T
Other languages
English (en)
Inventor
Nozulak Joachim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TR200401007T4 publication Critical patent/TR200401007T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Bulus; yeni azabisiklik karbamatlar, bunlarin hazirlanmalari, farmasötikler olarak kullanimlari ve bahsedilen azabisiklik karbamatlari içeren farmasötik kompozisyonlar ile ilgilidir. özellikle, bulus psikotik ve nörodejeneratif rahatsizliklarin tedavisinde kullanim için, serbest baz veya asit eklenik tuz formundaki formül(1) deki bir bilesigi saglamakta olup, formül (I) içerisindeki n, 1 veya 2' dir, R1 R2 ve R3; bagimsiz olarak, hidrojen veya (C1-4) alkildir ve A, asagida formül (I)' in altinda belirtilmis formüllerdeki bir grup olup, söz konusu formüller içerisindeki m; 1, 2 veya 3' tür, X; O, S, NH veya CH2' dir ve R4 ve R5; bagimsiz olarak, hidrojen, halojen, hidroksi, (C1-4) alkil, (C1-4) alkoksi, (C1-4) alkiltiyo, (C1-4) alkilamino, nitro, triflorometil veya fenildir.
TR2004/01007T 2000-05-05 2001-05-03 Azabisiklik karbamatlar ve bunların, alfa-7 nikotinik asetilkolin reseptör agonistleri olarak kullanımları TR200401007T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0010955.3A GB0010955D0 (en) 2000-05-05 2000-05-05 Organic compounds

Publications (1)

Publication Number Publication Date
TR200401007T4 true TR200401007T4 (tr) 2004-07-21

Family

ID=9891092

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/01007T TR200401007T4 (tr) 2000-05-05 2001-05-03 Azabisiklik karbamatlar ve bunların, alfa-7 nikotinik asetilkolin reseptör agonistleri olarak kullanımları

Country Status (29)

Country Link
US (1) US6780861B2 (tr)
EP (1) EP1282620B1 (tr)
JP (1) JP4898062B2 (tr)
KR (1) KR20020093974A (tr)
CN (1) CN1167703C (tr)
AR (1) AR028073A1 (tr)
AT (1) ATE263167T1 (tr)
AU (2) AU6225701A (tr)
BR (1) BR0110521A (tr)
CA (1) CA2407972C (tr)
CZ (1) CZ20023622A3 (tr)
DE (1) DE60102581T2 (tr)
DK (1) DK1282620T3 (tr)
ES (1) ES2218418T3 (tr)
GB (1) GB0010955D0 (tr)
HK (1) HK1054223B (tr)
HU (1) HUP0301866A2 (tr)
IL (1) IL152417A0 (tr)
MX (1) MXPA02010892A (tr)
NO (1) NO20025280D0 (tr)
NZ (1) NZ522226A (tr)
PE (1) PE20020221A1 (tr)
PL (1) PL357435A1 (tr)
PT (1) PT1282620E (tr)
RU (1) RU2002131886A (tr)
SK (1) SK15612002A3 (tr)
TR (1) TR200401007T4 (tr)
WO (1) WO2001085727A1 (tr)
ZA (1) ZA200208969B (tr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262265A (ja) * 1985-09-13 1987-03-18 Hitachi Ltd 復水器自動検査補修システム
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
JP2005518347A (ja) * 2001-11-02 2005-06-23 ジー．ディー． サール エルエルシー 頂端ナトリウム共依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US6852716B2 (en) * 2002-02-15 2005-02-08 Pfizer Inc Substituted-aryl compounds for treatment of disease
WO2003070731A2 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
DE10234424A1 (de) * 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
PL210065B1 (pl) 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
CN102657651A (zh) 2002-12-06 2012-09-12 范因斯坦医学研究院 用α 7受体结合胆碱能激动剂抑制炎症
EP1611128A2 (en) * 2003-03-28 2006-01-04 Pharmacia & Upjohn Company LLC Positive allosteric modulators of the nicotinic acetylcholine receptor
BRPI0417323A (pt) 2003-12-22 2007-03-27 Memory Pharm Corp indóis, 1h-indazóis, 1,2-benzisoxazóis, e 1,2-benzisotiazóis, composto, composição farmacêutica e usos dos mesmos
US20050170360A1 (en) * 2004-01-30 2005-08-04 Papke Roger L. Variant neuronal nicotinic alpha-7 receptor and methods of use
US7674899B2 (en) 2004-02-04 2010-03-09 Neurosearch A/S Dimeric azacyclic compounds and their use
CA2560741C (en) 2004-03-25 2013-08-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
JP2007534692A (ja) * 2004-04-22 2007-11-29 メモリー・ファーマシューティカルズ・コーポレイション インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用
DE602005027452D1 (de) * 2004-05-07 2011-05-26 Memory Pharm Corp 1h-indazole, benzothiazole, 1,2-benzisoxazole, 1,2-benzisothiazole und chromone und deren herstellung und verwendungen
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
AU2005319248A1 (en) * 2004-12-22 2006-06-29 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CN105687190A (zh) 2008-11-19 2016-06-22 福拉姆医药股份有限公司 用(R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺及其可药用盐治疗认知障碍
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
PE20120324A1 (es) * 2009-05-11 2012-04-17 Envivo Pharmaceuticals Inc Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos
US20120157464A1 (en) 2009-07-23 2012-06-21 Novartis Ag Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives for the treatment or prevention of ataxia
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
JP5633405B2 (ja) * 2010-02-18 2014-12-03 Jsr株式会社 新規化合物、感放射線性組成物及び硬化膜
WO2011119310A1 (en) * 2010-03-26 2011-09-29 Corning Incorporated Low nonlinearity long haul optical transmission system
KR20180101641A (ko) 2010-05-17 2018-09-12 포럼 파마슈티칼즈 인크. (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
BR112013001939A2 (pt) 2010-07-26 2017-07-11 Envivo Pharmaceuticals Inc tratamento de distúrbios cognitivos com determinados agonistas receptores de ácido alfa-7-nicotínico em combinação com inibidres de acetilcolinesterase
MX2013008704A (es) * 2011-01-27 2013-08-21 Novartis Ag Uso de activadores del receptor de acetil-colina nicotinico alfa-7.
MY173998A (en) * 2011-03-18 2020-03-03 Genzyme Corp Glucosylceramide synthase inhibitors
MX2013010698A (es) * 2011-03-18 2014-02-17 Novartis Ag Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson.
KR20140019409A (ko) 2011-04-29 2014-02-14 키에시 파르마슈티시 엣스. 피. 에이. 알칼로이드 에스텔 및 카바메이트 유도체와 그들의 의약조성물
CA2852268C (en) * 2011-10-20 2020-08-25 Novartis Ag Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
EP3461481A1 (en) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
CA2894384C (en) 2012-12-11 2018-03-06 Novartis Ag Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
KR101879921B1 (ko) * 2013-01-15 2018-07-18 노파르티스 아게 기면증의 치료를 위한 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도
JP6338223B2 (ja) 2013-01-15 2018-06-06 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体アゴニストの使用
ES2865736T3 (es) * 2013-01-15 2021-10-15 Novartis Ag Uso de agonistas del receptor de acetilcolina nicotínico alfa 7
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
EP4100009A1 (en) 2020-02-03 2022-12-14 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
CA3186766A1 (en) 2020-07-24 2022-01-27 Danielle Combessis Pharmaceutical compositions comprising venglustat

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
WO1995006635A1 (en) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1996008468A1 (en) 1994-09-14 1996-03-21 H. Lundbeck A/S Carbamoyloxy amine compounds
GB9525261D0 (en) 1995-12-11 1996-02-07 Bayer Ag Carbamic acid derivatives
GB9526560D0 (en) * 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US6313247B1 (en) * 1996-06-05 2001-11-06 Wolfgang Lindner Cinchonan based chiral selectors for separation of stereoisomers
US6624173B1 (en) * 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
US6525065B1 (en) * 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US5988429A (en) * 1997-10-14 1999-11-23 Pharmadesign, Inc. Blister pack pill dispenser
US6599917B1 (en) * 1999-09-28 2003-07-29 Eisai Co., Ltd. Quinuclidine compounds and drugs containing the same as the active ingredient
US6479510B2 (en) * 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
GB0109871D0 (en) * 2001-04-20 2001-06-13 Glaxo Group Ltd Metering method for particulate material

Also Published As

Publication number Publication date
DE60102581D1 (de) 2004-05-06
WO2001085727A1 (en) 2001-11-15
EP1282620A1 (en) 2003-02-12
DE60102581T2 (de) 2005-02-03
CN1427840A (zh) 2003-07-02
CZ20023622A3 (cs) 2003-02-12
BR0110521A (pt) 2003-04-08
NO20025280L (no) 2002-11-04
MXPA02010892A (es) 2003-03-27
AU2001262257B2 (en) 2004-11-04
HK1054223B (en) 2005-03-04
ES2218418T3 (es) 2004-11-16
AU6225701A (en) 2001-11-20
CN1167703C (zh) 2004-09-22
RU2002131886A (ru) 2004-04-10
US20030166654A1 (en) 2003-09-04
IL152417A0 (en) 2003-05-29
GB0010955D0 (en) 2000-06-28
PT1282620E (pt) 2004-07-30
PL357435A1 (en) 2004-07-26
JP2003532731A (ja) 2003-11-05
NO20025280D0 (no) 2002-11-04
CA2407972C (en) 2010-03-09
US6780861B2 (en) 2004-08-24
PE20020221A1 (es) 2002-04-23
NZ522226A (en) 2004-08-27
ATE263167T1 (de) 2004-04-15
ZA200208969B (en) 2003-10-07
CA2407972A1 (en) 2001-11-15
EP1282620B1 (en) 2004-03-31
SK15612002A3 (sk) 2003-04-01
JP4898062B2 (ja) 2012-03-14
HK1054223A1 (en) 2003-11-21
AR028073A1 (es) 2003-04-23
DK1282620T3 (da) 2004-07-19
KR20020093974A (ko) 2002-12-16
HUP0301866A2 (hu) 2003-09-29

Similar Documents

Publication Publication Date Title
TR200401007T4 (tr) Azabisiklik karbamatlar ve bunların, alfa-7 nikotinik asetilkolin reseptör agonistleri olarak kullanımları
ATE203524T1 (de) Chinazolin-derivate
DE60033857D1 (de) Derivate des N-((Chinolinyl)oxy)-phenyl)-Harnstoffs und des N-((Chinazolinyl)oxy)-phenyl)-Harnstoffs mit Antitumor Aktivität
CA2272291A1 (en) Crf antagonistic quino- and quinazolines
WO1999042465A3 (en) Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
MXPA02012425A (es) Compuestos nuevos.
ATE325796T1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
ATE277889T1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
PE20010638A1 (es) Imidazo-5-il-aminas biciclicas, medicamentos que las contienen, su uso para la preparacion de medicamentos y procedimiento para su preparacion
MXPA04003008A (es) Compuestos pirimidina de anillo fusionado alquinilado como inhibidores de metaloproteasa 13 de la matriz.
NZ503912A (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists
NZ528997A (en) Sulfonamides
EE200000059A (et) Tetrahüdro-gamma-karboliinid
ES8307244A1 (es) Un procedimiento para la preparacion de nuevos derivados de benzamida.
ATE270289T1 (de) Heteroaryloxypropanolamine als beta3- adrenergischer rezeptor-agonisten
JO2235B1 (en) Derivatives of phenyl
RU2396264C2 (ru) Производные хромана и их применение в качестве лигандов 5-нт рецептора
DK0925295T3 (da) Derivater af N-benzensulfonyl-L-prolin som antagonister af receptoren B2 for bradykinin
NZ337749A (en) Benzimidazole derivative and their use in allergy-related disease
PT732332E (pt) Benzotienilpiperazinas substituidas sua utilizacao como medicamentos e processos para a sua preparacao
WO2002074777A3 (en) Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity
MY118312A (en) Angiogenesis inhibiting 5- substituted- 1,2,4- thiadiazolyl derivatives
AR020294A1 (es) COMPUESTOS DERIVADOS DE 1-TRIFLUOROMETIL-4-HIDROXI-7-PIPERIDINIL-AMINOMETILCROMANO, COMPOSICION FARMACEUTICA Y USO EN LA PREPARACIoN DE MEDICAMENTOS.
AP9801410A0 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists.